Profile data is unavailable for this security.
About the company
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
- Revenue in USD (TTM)145.24m
- Net income in USD-376.33m
- Incorporated2008
- Employees380.00
- LocationTravere Therapeutics Inc3611 Valley Centre Dr, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (760) 260-8600
- Fax+1 (302) 645-1280
- Websitehttps://travere.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cartesian Therapeutics Inc | 26.00m | -219.71m | 455.58m | 38.00 | -- | -- | -- | 17.52 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Theravance Biopharma Inc | 57.42m | -55.19m | 459.38m | 99.00 | -- | 2.14 | -- | 8.00 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
PepGen Inc | 0.00 | -78.63m | 459.94m | 64.00 | -- | 3.12 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
Fate Therapeutics Inc | 63.53m | -160.93m | 462.10m | 181.00 | -- | 1.09 | -- | 7.27 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
C4 Therapeutics Inc | 20.76m | -132.49m | 462.37m | 145.00 | -- | 1.66 | -- | 22.28 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
Editas Medicine Inc | 78.12m | -153.22m | 466.27m | 265.00 | -- | 1.33 | -- | 5.97 | -2.06 | -2.06 | 1.03 | 4.27 | 0.1542 | -- | 10.19 | 294,803.80 | -30.24 | -29.85 | -34.43 | -33.19 | -- | -- | -196.13 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Neurogene Inc | 0.00 | -36.32m | 471.27m | 91.00 | -- | 2.53 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
Third Harmonic Bio Inc | 0.00 | -30.82m | 476.36m | 30.00 | -- | 1.74 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
Travere Therapeutics Inc | 145.24m | -376.33m | 476.44m | 380.00 | -- | 2.35 | -- | 3.28 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Voyager Therapeutics Inc | 250.01m | 132.33m | 479.16m | 162.00 | 2.98 | 1.64 | 3.50 | 1.92 | 2.96 | 2.96 | 5.56 | 5.37 | 0.9792 | -- | 5.97 | 1,543,259.00 | 51.83 | 0.6378 | 70.85 | 0.8203 | -- | -- | 52.93 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Taysha Gene Therapies Inc | 15.45m | -111.57m | 480.64m | 52.00 | -- | 6.41 | -- | 31.11 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Fulcrum Therapeutics Inc | 2.81m | -97.34m | 481.69m | 76.00 | -- | 2.04 | -- | 171.73 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Arbutus Biopharma Corp | 18.14m | -72.85m | 488.27m | 73.00 | -- | 4.34 | -- | 26.92 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
Larimar Therapeutics Inc | 0.00 | -36.95m | 495.41m | 42.00 | -- | 4.17 | -- | -- | -0.8416 | -0.8416 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -33.24 | -42.22 | -36.56 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Dec 2023 | 7.38m | 9.70% |
Deep Track Capital LPas of 31 Dec 2023 | 7.37m | 9.69% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 6.22m | 8.17% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 5.35m | 7.03% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 5.33m | 7.00% |
Macquarie Investment Management Business Trustas of 31 Dec 2023 | 4.75m | 6.24% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 3.95m | 5.20% |
Renaissance Technologies LLCas of 31 Dec 2023 | 3.08m | 4.05% |
Rock Springs Capital Management LPas of 31 Dec 2023 | 2.77m | 3.64% |
Pictet Asset Management SAas of 31 Dec 2023 | 2.37m | 3.11% |